Product Highlight - Gardasil 9

Gardasil 9 is indicated for active immunisation of:

• Individuals age ≥9 years against the following HPV diseases:
   - Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types.
   - Genital warts (Condyloma acuminata) caused by specific HPV types.
• Individuals from the age of 9-45 years against the following HPV diseases:
   - Cancers affecting the oropharynx and other head and neck sites caused by HPV types 16, 18, 31, 33, 45, 52, and 58.

The indication for cancers affecting the oropharynx and other head and neck sites is approved by the United States under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication in the United States may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Before prescribing, please consult the full prescribing information.

Reference: GARDASIL 9 [prescribing information]. Merck Sharp & Dohme (Asia) Ltd; Sep 2022.

This material is made available with the support from MSD (HK-GSL-00674 May/2023)